SK284243B6 - Kompozícia na báze fluoroéterov a spôsoby inhibície ich degradácie v prítomnosti Lewisovej kyseliny - Google Patents
Kompozícia na báze fluoroéterov a spôsoby inhibície ich degradácie v prítomnosti Lewisovej kyseliny Download PDFInfo
- Publication number
- SK284243B6 SK284243B6 SK861-99A SK86199A SK284243B6 SK 284243 B6 SK284243 B6 SK 284243B6 SK 86199 A SK86199 A SK 86199A SK 284243 B6 SK284243 B6 SK 284243B6
- Authority
- SK
- Slovakia
- Prior art keywords
- water
- sevoflurane
- lewis acid
- degradation
- bottles
- Prior art date
Links
- 239000002841 Lewis acid Substances 0.000 title claims abstract description 71
- 150000007517 lewis acids Chemical class 0.000 title claims abstract description 71
- 229920001774 Perfluoroether Polymers 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000006731 degradation reaction Methods 0.000 title claims description 40
- 230000015556 catabolic process Effects 0.000 title claims description 38
- 238000000034 method Methods 0.000 title claims description 12
- 230000002401 inhibitory effect Effects 0.000 title description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 77
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- 239000003112 inhibitor Substances 0.000 claims abstract description 41
- 230000003444 anaesthetic effect Effects 0.000 claims abstract description 11
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims abstract description 3
- 229960002216 methylparaben Drugs 0.000 claims abstract description 3
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims abstract description 3
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000005844 Thymol Substances 0.000 claims abstract 2
- 229960004134 propofol Drugs 0.000 claims abstract 2
- 229960000790 thymol Drugs 0.000 claims abstract 2
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 claims description 79
- 229960002078 sevoflurane Drugs 0.000 claims description 74
- 239000011521 glass Substances 0.000 claims description 27
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 17
- 239000007857 degradation product Substances 0.000 claims description 17
- 238000011160 research Methods 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 238000004817 gas chromatography Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 6
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 19
- LFIIIPMEVREURN-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoro-2-[2-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)ethoxy]propane Chemical compound FC(F)(F)C(C(F)(F)F)OCCOC(C(F)(F)F)C(F)(F)F LFIIIPMEVREURN-UHFFFAOYSA-N 0.000 description 10
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 10
- 239000003708 ampul Substances 0.000 description 7
- XICBRSPNSAUHFY-UHFFFAOYSA-N [1,1,1,3,3,3-hexafluoro-2-(fluoromethyl)propan-2-yl]oxymethanol Chemical compound OCOC(CF)(C(F)(F)F)C(F)(F)F XICBRSPNSAUHFY-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910052593 corundum Inorganic materials 0.000 description 5
- 230000000087 stabilizing effect Effects 0.000 description 5
- 229910001845 yogo sapphire Inorganic materials 0.000 description 5
- OHHWIUWMPLFBMA-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoro-2-(1,1,1,3,3,3-hexafluoropropan-2-yloxymethoxy)propane Chemical compound FC(F)(F)C(C(F)(F)F)OCOC(C(F)(F)F)C(F)(F)F OHHWIUWMPLFBMA-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- -1 2,2-difluoroethyl ether Chemical compound 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 229940035674 anesthetics Drugs 0.000 description 3
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003193 general anesthetic agent Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 231100000481 chemical toxicant Toxicity 0.000 description 2
- DPYMFVXJLLWWEU-UHFFFAOYSA-N desflurane Chemical compound FC(F)OC(F)C(F)(F)F DPYMFVXJLLWWEU-UHFFFAOYSA-N 0.000 description 2
- 229960003537 desflurane Drugs 0.000 description 2
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 2
- 229960000305 enflurane Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960002455 methoxyflurane Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HYIHKHMDVJQOCT-UHFFFAOYSA-N 3-chloro-1-(3-chloro-1,1,2,2,3-pentafluoropropoxy)-1,1,2,2,3-pentafluoropropane Chemical compound FC(Cl)C(F)(F)C(F)(F)OC(F)(F)C(F)(F)C(F)Cl HYIHKHMDVJQOCT-UHFFFAOYSA-N 0.000 description 1
- IOAISUCAQCEHTA-UHFFFAOYSA-N 5-methyl-2-propan-2-ylphenol Chemical compound CC(C)C1=CC=C(C)C=C1O.CC(C)C1=CC=C(C)C=C1O IOAISUCAQCEHTA-UHFFFAOYSA-N 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- RNQKTBRQJCQNFK-UHFFFAOYSA-N CC(C)(C)C1(CC=C(C=C1C(C)(C)C)C)O.OCC1=CC=CC=C1 Chemical class CC(C)(C)C1(CC=C(C=C1C(C)(C)C)C)O.OCC1=CC=CC=C1 RNQKTBRQJCQNFK-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910008051 Si-OH Inorganic materials 0.000 description 1
- 229910008284 Si—F Inorganic materials 0.000 description 1
- 229910006358 Si—OH Inorganic materials 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000004773 chlorofluoromethyl group Chemical group [H]C(F)(Cl)* 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- CKFGINPQOCXMAZ-UHFFFAOYSA-N formaldehyde hydrate Natural products OCO CKFGINPQOCXMAZ-UHFFFAOYSA-N 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000011124 type III (regular soda lime glass) Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Catalysts (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/789,679 US5990176A (en) | 1997-01-27 | 1997-01-27 | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
| PCT/US1998/001376 WO1998032430A1 (fr) | 1997-01-27 | 1998-01-23 | Compositions de fluoroether et procedes d'inhibition de leur degradation en presence d'un acide de lewis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK86199A3 SK86199A3 (en) | 2000-06-12 |
| SK284243B6 true SK284243B6 (sk) | 2004-12-01 |
Family
ID=25148366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK861-99A SK284243B6 (sk) | 1997-01-27 | 1998-01-23 | Kompozícia na báze fluoroéterov a spôsoby inhibície ich degradácie v prítomnosti Lewisovej kyseliny |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US5990176A (fr) |
| EP (2) | EP0967975B1 (fr) |
| JP (5) | JP3183520B2 (fr) |
| KR (1) | KR100368672B1 (fr) |
| CN (3) | CN1152674C (fr) |
| AR (2) | AR011090A1 (fr) |
| AT (2) | ATE320798T1 (fr) |
| AU (1) | AU726733B2 (fr) |
| BG (2) | BG109751A (fr) |
| BR (1) | BR9806996A (fr) |
| CA (2) | CA2278133C (fr) |
| CO (1) | CO4920220A1 (fr) |
| CZ (1) | CZ297092B6 (fr) |
| DE (2) | DE69833884T2 (fr) |
| DK (2) | DK0967975T3 (fr) |
| ES (2) | ES2170474T3 (fr) |
| GR (1) | GR3036190T3 (fr) |
| HU (1) | HUP0002101A3 (fr) |
| IL (1) | IL130150A (fr) |
| NO (1) | NO993606L (fr) |
| NZ (1) | NZ335994A (fr) |
| PL (1) | PL334477A1 (fr) |
| PT (2) | PT967975E (fr) |
| SK (1) | SK284243B6 (fr) |
| TR (1) | TR199901579T2 (fr) |
| WO (1) | WO1998032430A1 (fr) |
| ZA (1) | ZA98418B (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990176A (en) * | 1997-01-27 | 1999-11-23 | Abbott Laboratories | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
| US6074668A (en) * | 1998-01-09 | 2000-06-13 | Abbott Laboratories | Container for an inhalation anesthetic |
| US6162443A (en) * | 1998-01-09 | 2000-12-19 | Abbott Laboratories | Container for an inhalation anesthetic |
| US20030200963A1 (en) * | 1998-01-09 | 2003-10-30 | Flament-Garcia Mary Jane | Container for an inhalation anesthetic |
| US6979456B1 (en) | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
| EP1105096B1 (fr) | 1998-08-19 | 2003-10-29 | Skyepharma Canada Inc. | Dispersions aqueuses injectables de propofol |
| EP1530336B1 (fr) | 1999-01-08 | 2009-06-10 | Sony Deutschland GmbH | Structure de préambule de synchronisation pour système MDFO |
| TW523409B (en) | 2000-09-15 | 2003-03-11 | Baxter Int | Container for inhalation anesthetic |
| BR0303489A (pt) * | 2003-09-10 | 2005-07-05 | Cristalia Prod Quimicos Farm | Composição farmacêutica estabilizada de composto flúor-éter e método para inibir a degradação de composto flúor-éter. uso de agente estabilizante para inibir a degradação de composto flúor éter |
| US7816409B2 (en) * | 2003-09-10 | 2010-10-19 | Cristalia Productos Quimicos Farmaceuticos Ltda | Stable pharmaceutical composition of fluoroether compound for anesthetic use method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound |
| EP1871734A4 (fr) * | 2005-04-18 | 2010-08-04 | Piramal Critical Care Inc | Preparation de sevoflurane avec un contenu en eau negligeable |
| WO2009049460A1 (fr) * | 2007-10-15 | 2009-04-23 | Jiangsu Hengrui Medicine Co., Ltd. | Nouveau matériau conditionné de sévoflurane |
| CN107661293A (zh) * | 2008-01-22 | 2018-02-06 | 得克萨斯大学体系董事会 | 用于局部麻醉和/或疼痛缓解的含有萃取溶剂的挥发性麻醉剂组合物 |
| US20090275785A1 (en) * | 2008-05-01 | 2009-11-05 | Barry Jones | Distillation Method For The Purification Of Sevoflurane And The Maintenance Of Certain Equipment That May Be Used In The Distillation Process |
| US8563115B2 (en) | 2008-08-12 | 2013-10-22 | Xerox Corporation | Protective coatings for solid inkjet applications |
| US8092822B2 (en) * | 2008-09-29 | 2012-01-10 | Abbott Cardiovascular Systems Inc. | Coatings including dexamethasone derivatives and analogs and olimus drugs |
| US8283643B2 (en) * | 2008-11-24 | 2012-10-09 | Cymer, Inc. | Systems and methods for drive laser beam delivery in an EUV light source |
| US8191992B2 (en) * | 2008-12-15 | 2012-06-05 | Xerox Corporation | Protective coatings for solid inkjet applications |
| US9278048B2 (en) * | 2009-05-06 | 2016-03-08 | Baxter International, Inc. | Pharmaceutical product and method of use |
| US9102604B1 (en) | 2010-02-15 | 2015-08-11 | Baxter International Inc. | Methods for cleaning distilling columns |
| CN105193774B (zh) * | 2015-09-21 | 2018-01-16 | 山东新时代药业有限公司 | 一种七氟烷吸入剂 |
| CN105106182B (zh) * | 2015-09-21 | 2017-12-29 | 山东新时代药业有限公司 | 七氟烷吸入剂 |
| BE1024432B1 (fr) * | 2016-11-02 | 2018-02-19 | Central Glass Company, Limited | Procédé pour le lavage de récipient de stockage de sévoflurane et procédé pour le stockage de sévoflurane |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2992276A (en) * | 1959-05-20 | 1961-07-11 | Du Pont | Process for preparing polyfluoro alkyl compounds |
| US3527813A (en) * | 1966-10-03 | 1970-09-08 | Air Reduction | 1,1,2 - trifluoro - 2 - chloroethyl difluoromethyl ether and its method of preparation |
| US3689571A (en) * | 1970-07-31 | 1972-09-05 | Baxter Laboratories Inc | Fluorinated ether |
| GB1499818A (en) * | 1974-12-06 | 1978-02-01 | Ici Ltd | Anaesthetic composition |
| US4250334A (en) * | 1979-12-26 | 1981-02-10 | Baxter Travenol Laboratories, Inc. | Method of synthesizing fluoromethylhexafluoroisopropyl ether |
| US4469898A (en) * | 1979-12-26 | 1984-09-04 | Baxter Travenol Laboratories, Inc. | Method of synthesizing fluoromethylhexafluoroisopropyl ether |
| JP2786108B2 (ja) * | 1994-03-31 | 1998-08-13 | セントラル硝子株式会社 | フルオロメチル−１，１，１，３，３，３−ヘキサフルオロイソプロピルエーテルの精製方法 |
| IT1270239B (it) * | 1994-06-17 | 1997-04-29 | Zambon Spa | Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo |
| US5990176A (en) * | 1997-01-27 | 1999-11-23 | Abbott Laboratories | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
-
1997
- 1997-01-27 US US08/789,679 patent/US5990176A/en not_active Expired - Lifetime
-
1998
- 1998-01-19 ZA ZA98418A patent/ZA98418B/xx unknown
- 1998-01-23 DE DE69833884T patent/DE69833884T2/de not_active Expired - Lifetime
- 1998-01-23 KR KR10-1999-7006724A patent/KR100368672B1/ko not_active Ceased
- 1998-01-23 JP JP53216898A patent/JP3183520B2/ja not_active Expired - Lifetime
- 1998-01-23 AT AT01107733T patent/ATE320798T1/de active
- 1998-01-23 SK SK861-99A patent/SK284243B6/sk not_active IP Right Cessation
- 1998-01-23 IL IL13015098A patent/IL130150A/en not_active IP Right Cessation
- 1998-01-23 TR TR1999/01579T patent/TR199901579T2/xx unknown
- 1998-01-23 CO CO98003122A patent/CO4920220A1/es unknown
- 1998-01-23 CN CNB98802053XA patent/CN1152674C/zh not_active Expired - Lifetime
- 1998-01-23 CA CA002278133A patent/CA2278133C/fr not_active Expired - Lifetime
- 1998-01-23 ES ES98902707T patent/ES2170474T3/es not_active Expired - Lifetime
- 1998-01-23 DE DE69800928T patent/DE69800928T2/de not_active Revoked
- 1998-01-23 PL PL98334477A patent/PL334477A1/xx not_active IP Right Cessation
- 1998-01-23 NZ NZ335994A patent/NZ335994A/xx not_active IP Right Cessation
- 1998-01-23 PT PT98902707T patent/PT967975E/pt unknown
- 1998-01-23 EP EP98902707A patent/EP0967975B1/fr not_active Revoked
- 1998-01-23 CA CA002626424A patent/CA2626424A1/fr not_active Abandoned
- 1998-01-23 AT AT98902707T patent/ATE201987T1/de not_active IP Right Cessation
- 1998-01-23 WO PCT/US1998/001376 patent/WO1998032430A1/fr not_active Ceased
- 1998-01-23 DK DK98902707T patent/DK0967975T3/da active
- 1998-01-23 CZ CZ0256199A patent/CZ297092B6/cs not_active IP Right Cessation
- 1998-01-23 PT PT01107733T patent/PT1114641E/pt unknown
- 1998-01-23 ES ES01107733T patent/ES2256104T3/es not_active Expired - Lifetime
- 1998-01-23 AU AU59300/98A patent/AU726733B2/en not_active Expired
- 1998-01-23 HU HU0002101A patent/HUP0002101A3/hu unknown
- 1998-01-23 EP EP01107733A patent/EP1114641B1/fr not_active Expired - Lifetime
- 1998-01-23 CN CNA2006101016375A patent/CN1899271A/zh active Pending
- 1998-01-23 DK DK01107733T patent/DK1114641T3/da active
- 1998-01-23 BR BR9806996-9A patent/BR9806996A/pt active IP Right Grant
- 1998-01-23 CN CNB2004100368062A patent/CN1321958C/zh not_active Expired - Lifetime
- 1998-01-26 AR ARP980100336A patent/AR011090A1/es active IP Right Grant
-
1999
- 1999-07-23 NO NO19993606A patent/NO993606L/no not_active Application Discontinuation
- 1999-08-10 BG BG109751A patent/BG109751A/bg unknown
- 1999-08-10 BG BG103656A patent/BG65414B1/bg unknown
- 1999-11-23 US US09/447,853 patent/US6288127B1/en not_active Expired - Lifetime
-
2000
- 2000-11-16 JP JP2000349024A patent/JP3664648B2/ja not_active Expired - Lifetime
-
2001
- 2001-07-06 GR GR20010401038T patent/GR3036190T3/el not_active IP Right Cessation
- 2001-08-08 US US09/924,573 patent/US6444859B2/en not_active Expired - Lifetime
-
2002
- 2002-07-03 US US10/190,271 patent/US6677492B2/en not_active Expired - Lifetime
-
2003
- 2003-06-26 US US10/606,821 patent/US20040048932A1/en not_active Abandoned
-
2005
- 2005-04-06 JP JP2005109476A patent/JP2005279283A/ja not_active Ceased
- 2005-12-27 JP JP2005374621A patent/JP2006143742A/ja not_active Ceased
- 2005-12-27 JP JP2005374622A patent/JP2006137769A/ja not_active Ceased
-
2006
- 2006-02-27 US US11/362,954 patent/US20060148906A1/en not_active Abandoned
- 2006-11-16 AR ARP060105042A patent/AR057610A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK284243B6 (sk) | Kompozícia na báze fluoroéterov a spôsoby inhibície ich degradácie v prítomnosti Lewisovej kyseliny | |
| JP2007505047A (ja) | 麻酔用フルオロエーテル化合物の安定した医薬組成物、フルオロエーテル化合物の安定化方法、フルオロエーテル化合物の分解を防止するための安定剤の使用 | |
| CA2352597C (fr) | Compositions de fluoroether et procedes d'inhibition de leur degradation en presence d'un acide de lewis | |
| MXPA99006919A (en) | Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid | |
| HK1108633B (en) | Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Assignment and transfer of rights |
Owner name: CENTRAL GLASS COMPANY, LTD., CHIYODA-KU, TOKYO, JP Free format text: FORMER OWNER: ABBOTT LABORATORIES, ABBOTT PARK, IL, US; CENTRAL GLASS COMPANY, LTD., CHIYODA-KU, TOKYO, JP Effective date: 20120801 Owner name: ABBVIE INC., NORTH CHICAGO, IL, US Free format text: FORMER OWNER: ABBOTT LABORATORIES, ABBOTT PARK, IL, US; CENTRAL GLASS COMPANY, LTD., CHIYODA-KU, TOKYO, JP Effective date: 20120801 |
|
| MK4A | Patent expired |
Expiry date: 20180123 |